13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00
- HK$30.19bn
- HK$24.04bn
- $838.00m
- 79
- 15
- 57
- 49
RCS - Hutchmed China Ltd - Sovleplenib NDA Granted Priority Review in China
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II/III Trial
AnnouncementRCS - Hutchmed China Ltd - Inclusion in National Reimbursement Drug List
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at Congresses
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO 2023
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - NDA Submission for Fruquintinib in Japan
AnnouncementREG - Hutchmed China Ltd - Director’s Share Dealing
AnnouncementRCS - Hutchmed China Ltd - Phase IIIb Savolitinib Results at WCLC 2023
AnnouncementRCS - Hutchmed China Ltd - Patient Enrollment Completed for Bridging Study
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - BTD in China for Savolitinib for Gastric Cancer
Announcement